CDSCO Examines Risks of Brand Name Extensions Across Different Drug Formulations
CDSCO has invited stakeholder feedback on drug brand name extensions amid concerns over therapeutic confusion and patient safety, with comments due by 17 July 2026.
active pharmaceutical ingredients